Xylasol 20 mg/ml, solution for injection for cattle, horses, dogs and cats

Authorised

- Xylazine hydrochloride

Product identification

Medicine name:
Xylasol 20 mg/ml, solution for injection for cattle, horses, dogs and cats
Xysol vet. 20 mg/ml injeksjonsvæske, oppløsning til storfe, hest, hund og katt

Active substance:
Xylazine hydrochloride

Target species:
Cattle
Horse
Dog
Cat

Route of administration:
Intramuscular use
Intravenous use
Subcutaneous use

Product details

Active substance and strength:
Xylazine hydrochloride
23.31 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Cattle**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day
- **Horse**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day

Intravenous use:

- **Cattle**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day
- **Horse**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day

Subcutaneous use:

- **Cattle**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day
- **Horse**
  - Milk. no withdrawal period — Should be 0 days
  - Meat and offal. 1 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QN05CM92

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Norway

Available in:
Norway

Package description:
Cardboard box containing 1 vial (uncoloured glass type II, closed with bromobutyl rubber stopper, secured with aluminium cap) filled with 50 ml
Cardboard box containing 1 vial (uncoloured glass type II, closed with bromobutyl rubber stopper, secured with aluminium cap) filled with 25 ml
Cardboard box containing 1 vial (uncoloured glass type II, closed with bromobutyl rubber stopper, secured with aluminium cap) filled with 10 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
CP-Pharma Handelsgesellschaft mbH

Marketing authorisation date:
22/05/2012

Manufacturing sites for batch release:
CP-Pharma Handelsgesellschaft mbH

Responsible authority:
Norwegian Medical Products Agency

Authorisation number:
10-8082

Date of authorisation status change:
22/02/2017

Reference member state:
Netherlands

Procedure number:
NL/V/0158/001

Concerned member states:
Austria Denmark Finland France Germany Hungary Norway Spain Sweden

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

108964 - par.pdf